226398-62-5

Basic information

• Product Name: 4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 4-(4-bromophenylsulfonyl)piperidine-1-carboxylate;tert-Butyl 4-(4-bromo-benzenesulfonyl)piperidine-1-carboxylate;1-Boc-4-(4-BroMobenzenesulfonyl)piperidine;1-Piperidinecarboxylic acid, 4-[(4-broMophenyl)sulfonyl]-, 1,1-diMethylethyl ester;1-Boc-4-(4-Bromobenzenesulfonyl)
• CAS NO: 226398-62-5
• Molecular Formula: C₁₆H₂₂BrNO₄S
• Molecular Weight: 404.32
• Mol File: 226398-62-5.mol

Chemical Properties

• Boiling Point: 510.504°C at 760 mmHg
• Flash Point: 262.543°C
• Appearance: /
• Density: 1.403
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(226398-62-5)
• EPA Substance Registry System: 4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(226398-62-5)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 226398-62-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of various organic compounds due to its unique chemical properties and reactivity.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is employed as a key intermediate in the development of pharmaceuticals, leveraging its structural features to construct novel drug candidates with potential therapeutic applications.
Used in Pharmaceutical Industry:
4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a chemical intermediate for the production of pharmaceuticals, contributing to the discovery and synthesis of new drugs with improved efficacy and safety profiles.
Used in Research and Development:
4-(4-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is also utilized in research and development settings as a tool to explore new chemical reactions and mechanisms, furthering the understanding of organic chemistry and its applications in various scientific disciplines.

InChI:InChI=1/C16H22BrNO4S/c1-16(2,3)22-15(19)18-10-8-14(9-11-18)23(20,21)13-6-4-12(17)5-7-13/h4-7,14H,8-11H2,1-3H3

Upstream product

• 911410-37-2 1-(4-hydroxypiperidin-1-yl)-2,2-dimethylpropan-1-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 226400-32-4 4-(4-bromobenzenesulfonyl)piperidine hydrochloride 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 106-53-6 para-bromobenzenethiol 
• 188527-03-9 4-(4-bromophenylsulfanyl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1350351-53-9 tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfonylpiperidine-1-carboxylate 
• 1350351-54-0 tert-butyl 4-[4-[5-amino-6-[2-(3-hydroxyphenyl)ethynyl]pyrazin-2-yl]phenyl]sulfonylpiperidine-1-carboxylate 
• 1450723-34-8 N-[[4-(4,4-difluorocyclohexyl)sulfonylphenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 1450724-22-7 C₂₀H₂₃N₃O₆S 
• 1450724-23-8 C₂₂H₂₇N₃O₆S 
• 1450723-38-2 N-[[4-[(1-acetyl-4-piperidyl)sulfonyl]phenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 1450723-40-6 N-[[4-[[1-(oxetan-3-yl)-4-piperidyl]suIfonyl]phenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 1450723-41-7 N-[[4-[(1-tetrahydropyran-4-yl-4-piperidyl)sulfonyl]phenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 1450723-42-8 N-[[4-[(1-methyl-4-piperidyl)sulfonyl]phenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 1450723-43-9 N-[[4-[(1-isopropyl-4-piperidyl)sulfonyl]phenyl]methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 1450723-83-7 1-(4-[[4-(aminomethyl)benzene]sulfonyl]piperidin-1-yl)ethan-1-one 
• 1450723-84-8 C₁₅H₂₂N₂O₃S 
• 1450723-85-9 C₁₅H₂₂N₂O₃S 
• 1450723-86-0 4-[1-(tetrahydropyran-4-yl)piperidine-4-sulfonyl]benzylamine 

Relevant articles and documents

Synthesis and Characterization of N-(4-(Piperidin-4-ylsulfonyl) phenyl)5-vinylpyrimidin-2-amine

Target product N-(4-(piperidin-4-ylsulfonyl)phenyl)5-vinylpyrimidin-2- amine (13) was synthesized using 6-oxopyran-3-carbaldehyde (M1) and 4-hydroxypiperidine (M2) as starting materials by a series of nucleophilic substitution and oxidation. Different aci

Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment

Monoacylglycerol lipase (MGL) inhibition provides a potential treatment approach to glaucoma through the regulation of ocular 2-arachidonoylglycerol (2-AG) levels and the activation of CB1 receptors. Herein, we report the discovery of new series of carbamates as highly potent and selective MGL inhibitors. The new inhibitors showed potent nanomolar inhibitory activity against recombinant human and purified rat MGL, were selective (>1000-fold) against serine hydrolases FAAH and ABHD6 and lacked any affinity for the cannabinoid receptors CB1 and CB2. Protein-based 1H NMR experiments indicated that inhibitor 2 rapidly formed a covalent adduct with MGL with a residence time of about 6 h. This interconversion process “intrinsic reversibility” was exploited by modifications of the ligand's size (length and bulkiness) to generate analogs with “tunable’ adduct residence time (τ). Inhibitor 2 was evaluated in a normotensive murine model for assessing intraocular pressure (IOP), which could lead to glaucoma, a major cause of blindness. Inhibitor 2 was found to decrease ocular pressure by ～4.5 mmHg in a sustained manner for at least 12 h after a single ocular application, underscoring the potential for topically-administered MGL inhibitors as a novel therapeutic target for the treatment of glaucoma.

UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF

Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea and amide-containing NAMPT inhibitors. An optimized 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived compound exhibited potent anti-NAMPT activity (18; BC NAMPT IC50 = 11 nM; PC-3 antiproliferative IC50 = 36 nM), satisfactory mouse PK properties, and was efficacious in a PC-3 mouse xenograft model. The crystal structure of another optimized compound (29; NAMPT IC50 = 10 nM; A2780 antiproliferative IC50 = 7 nM) in complex with the NAMPT protein was also determined.

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various dis

2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS

Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases. Formula (I):

THIAZOLE INHIBITORS TARGETING RESISTANT AND KINASE MUTATIONS

A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophobic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.

Phenylsulphonyl derivatives as 5-HT receptor ligands

A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2Areceptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.

4-(Phenylsulfonyl)piperidines: Novel, selective, and bioavailable 5-HT2A receptor antagonists

On the basis of a spirocyclic ether screening lead, a series of acyclic sulfones have been identifed as high-affinity, selective 5-HT2A receptor antagonists. Bioavailability lacking in the parent, 1-(2-(2,4-difluorophenyl)ethyl)-4-(phenylsulfon